Oruka Therapeutics (ORKA) Hits Record High on Stellar Clinical Trial Result

Oruka Therapeutics Inc. (NASDAQ:ORKA) is one of the 10 Stocks Racking Up Monster Gains.

Oruka Therapeutics soared to a new record high on Monday, as investors positioned portfolios following positive results from the clinical study of its psoriasis treatment candidate, ORKA-001.

In an updated report, Oruka Therapeutics Inc. (NASDAQ:ORKA) said that 40 of the 63 enrolled patients treated with ORKA-001 achieved the primary endpoint of PASI 100 at Week 16, representing a complete skin clearance.

BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz

Photo by Roger Brown on Pexels

Based on a cross-trial comparison, ORKA-001 demonstrated numerically higher rates of skin clearance than all other IL-23p19 inhibitors.

Additionally, ORKA-001 recorded a safety profile and recorded no serious treatment-emergent adverse effects.

Following the news, shares of Oruka Therapeutics Inc. (NASDAQ:ORKA) climbed to their highest price of $91 in intra-day trading on Monday before paring gains to finish the session just up by 10.66 percent at $76.39 apiece.

“These data reached the top end of what we could have expected from ORKA-001 across efficacy, tolerability, and potential for long-lasting response,” Oruka Therapeutics Inc. (NASDAQ:ORKA) Chief Medical Officer Joana Goncalves said.

“We’re thrilled with the profile that is emerging for this program and are excited to see how the data matures with longer-term follow-up,” she added.

Longer-term data from the study, covering 28 weeks of treatment, is set to be provided in the second half of the year.

While we acknowledge the risk and potential of ORKA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ORKA and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.